$ALXO News

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer

ALX Oncology to Present at Upcoming Investor Conferences in September

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel

ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman

ALX Oncology: Rebuilding From Critical Setbacks

ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs

ALX Oncology (ALXO) Q1 2026 Earnings Transcript

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary

ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript

ALX Oncology Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation

ALX Oncology Q1 Earnings Call Highlights

ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate

Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock